histochemistry Archives - The Dark Intelligence Group

TAG:

histochemistry

Digital Pathology Can Be Transformative for Labs

By Joseph Burns | From the Volume XXIV No. 9 – June 26, 2017 Issue

CEO SUMMARY: Across the nation, pathologists are at a crossroads. Now that the FDA has cleared a digital pathology and whole slide imaging (WSI) system for use in primary diagnosis, should they adopt this technology sooner or wait until later? One pathologist who has worked with WSI for m…

In Texas, Questions for UnitedHealth, BeaconLBS

By Joseph Burns | From the Volume XXIV No. 1 – January 9, 2017 Issue

CEO SUMMARY: As of January 1, 2017, clinical laboratories and pathology groups in Texas will find it more difficult to serve the 500,000 patients enrolled in UnitedHealthcare’s fully-insured commercial plans in the Lone Star State. That’s because—just as it did in Florida—UnitedHe…

At Mid-Year, Labs Struggle to Get Paid for Many Tests

By Joseph Burns | From the Volume XXI No. 10 – July 21, 2014 Issue

CEO SUMMARY: At a recent coding and billing conference, pathology and lab clients of one of the nation’s largest revenue management companies agreed that three trends have caused lower revenues since the start of 2014. One trend seen by labs involves higher deductibles and copayments fr…

Local Labs vs. Central Labs Assessed in HER2 Test Study

By Robert Michel | From the Volume XXI No. 9 – June 30, 2014 Issue

WHEN IT COMES TO HER2NEU TESTING, a study of accuracy just published by the journal Cancer may raise interesting questions for pathology groups across the nation. “Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2- negative breast …

Eastern Canada’s Latest Lab Errors Get Attention

By Joseph Burns | From the Volume XXI No. 4 – March 17, 2014 Issue

CEO SUMMARY: Authorities for Eastern Health in Newfoundland and Labrador province in Canada are conducting a root cause analysis after finding discrepancies in breast cancer testing that affected nine patients. Health officials said these cases were discovered as a result of an improved q…

ACLA, CAP Comment on Final 2014 Medicare Rules

By Joseph Burns | From the Volume XX, No. 16 – December 2, 2013 Issue

CEO SUMMARY: On November 27, as the nation prepared for the Thanksgiving holiday, the federal Centers for Medicare & Medicaid Services (CMS) announced the long-awaited final rules for 2014. Early analysis of the 1,300 pages of rules CMS released indicates that the agency moderated one…

Ottawa Pathology Lab Cuts Turnaround Time By More Than 50%

By Joseph Burns | From the Volume XX No.14 – October 21, 2013 Issue

CEO Summary: Pathologists at Ottawa Hospital not only must handle a large volume of specimens regularly, but are experiencing a 14% per year growth in the number of specimens. Last year, when the average turnaround time for a case was nine days, the pathology department embarked …

Why One Molecular Diagnostics Company Closed Its Doors

By Joseph Burns | From the Volume XX No. 7 – May 28, 2013 Issue

CEO SUMMARY: When executives closed the doors of Pathwork Diagnostics last month, the simple explanation was that reimbursement for its proprietary molecular diagnostic test was inadequate. Indeed, that was part of the story. But other factors played significant roles in impeding…

Aetna To Lower Lab Test Prices, New Fees Are Effective on July 1

By Robert Michel | From the Volume XX No. 7 – May 28, 2013 Issue

IN RECENT MONTHS, labs are reporting the receipt of letters from Aetna, Inc., announcing that it will pay dramatically less than Medicare prices for many key lab tests. Aetna said that these lower prices will take effect on July 1, 2013. Three examples illustrate the deep fee cuts t…

Pathologists in China, U.S. Linked By Digital Pathology

By Robert Michel | From the Volume XIX No. 12 – August 27, 2012 Issue

CEO Summary: It is one of the first clinical collaborations of this type to be anchored by use of digital pathology. Pathologists at the medical schools of the Second Affiliated Hospital of Zhejiang University in Hangzhou, China, and the University of California Los Angeles (UCLA) are exc…

Volume XXVII No. 9 – June 22, 2020

THE NEWS ON THE SEROLOGICAL TEST FRONT is discouraging, even bleak, as THE DARK REPORT analyzes the outcome of the FDA’s own review of 11 tests previously listed as marketable. Only three tests passed the review, and yet a quality control expert consulted by THE DARK REPORT has dim views of the FDA’s testing operation, leading to even more doubts. Also, health insurers are scraping away at mandated COVID-19 test reimbursements, leaving lab revenues once again at their mercy.

See the full table of contents

How Much Laboratory Business Intelligence Have You Missed?

Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!

Need A Group Membership? Company Discounts are Available!

Sign up for TDR Insider

Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.

Topics

Visit The Dark Library